Ryan J. Sullivan

Harvard University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

14h-index4.5kcitations188works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(76), Cancer Immunotherapy and Biomarkers(29), Cancer, Lipids, and Metabolism(21), Cancer Mechanisms and Therapy(18), Synthesis and biological activity(17)

Publications188 total

KIT-Mutant Melanoma: Understanding the Pathway to Personalized Therapy
Cancers·2025· 1 citedOpen Access
Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy
2025Open Access
35 Real-world implementation of neoadjuvant immunotherapy and utility of ctDNA as a biomarker for recurrence
Regular and Young Investigator Award Abstracts·2025Open Access
A Second-Generation Route to the Cereblon Fragment of ARV-471, Vepdegestrant
Organic Process Research & Development·2025· 1 cited
Nascent Clinical Experience with Radiotherapeutic Management of Melanoma Brain Metastases in Patients Treated with Tumor-Infiltrating Lymphocyte (TIL) Therapy
International Journal of Radiation Oncology*Biology*Physics·2025Open Access
954P A randomized phase II study of autogene cevumeran plus pembrolizumab (pembro) versus pembro in 1L advanced melanoma (IMcode001)
Annals of Oncology·2025
Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma
Journal of Cancer·2025· 1 citedOpen Access
Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma
The Oncologist·2025· 3 citedOpen Access
A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma.
Journal of Clinical Oncology·2025· 2 cited
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: Results from a global multi-site chart review.
Journal of Clinical Oncology·2025
Eliminating Bimolecular Decomposition to Address Sustainability in Cross-Coupling: Supported Pd–PEPPSI–IPent<sup>Cl</sup>
Organic Letters·2025· 3 cited
Fabrication and functional validation of a hybrid biomimetic nanovaccine (HBNV) against Kit-mutant melanoma
Bioactive Materials·2024· 3 citedOpen Access
A continuous mode of action of nitric oxide in hard-to-heal wound healing
Journal of Wound Care·2024· 3 cited
144 Identifying a composite signature for predicting immune-related adverse events in advanced melanoma patients treated with immune checkpoint blockade
Regular and Young Investigator Award Abstracts·2024Open Access
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy
European Journal of Cancer·2024· 4 citedOpen Access
1102P Immune checkpoint inhibitor rechallenge after treatment with tumor-infiltrating lymphocytes in unresectable melanoma
Annals of Oncology·2024· 3 citedOpen Access
Periodontitis is an immune-related adverse event associated with immune checkpoint inhibitors: A multi-center cohort study
Cancer Letters·2024· 9 cited
General and Scalable Synthesis of 2-Aryl and 2-Alkyl Pyrimidines via an Electronically Tuned S<sub>N</sub>Ar Approach
Organic Letters·2024· 4 cited
Durchflussunterstützte Synthese von Heterocyclen bei hohen Temperaturen
2024
Supplementary Figures from Anti–PD-1–Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients
2023Open Access
page 1 of 10Next →

Frequent Co-authors

Stephen G. Newman(9), Keith T. Flaherty(8), Allan Timmermann(7), Halbert White(7), Marcel Schlaf(6), Dennie T. Frederick(5), Justine V. Cohen(3), Zeynep Eroglu(3), Richard D. Carvajal(3), D.V. Soldatov(3), Genevieve M. Boland(3), Reinhard Dummer(3), Antoine Hollebecque(3), Geoffrey I. Shapiro(3), Jordi Rodón(3), Michael J. Millward(3), Ling Gao(3), Amanda Sykes(3), Melinda D. Willard(3), Danni Yu(3)